Lantheus Holdings (LNTH) traded lower today as the market repriced the company’s next near-term pipeline catalyst after the FDA extended its review of LNTH-2501 (Gallium 68 edotreotide), also referred to as OCTEVY. The extension moves the target action date from March 29, 2026 to June 29, 2026, effectively pushing a key regulatory binary later into the year and reducing immediate catalyst-driven demand for the shares. (lantheusholdings.gcs-web.com)

For radiopharmaceutical developers, timing around PDUFA dates can drive positioning, particularly when a product is viewed as a meaningful portfolio expansion beyond an incumbent franchise. A three-month slip can translate into a later commercial launch window, a delayed contribution to 2026 sales, and a longer period of uncertainty around label, manufacturing, and rollout sequencing. The deferral also shifts attention to the company’s next decision points later in 2026, rather than delivering a March readout. (lantheusholdings.gcs-web.com)

The decline comes even as Lantheus has had recent regulatory progress elsewhere, including FDA approval of PYLARIFY TruVu on March 6, 2026. That approval helped reinforce the company’s innovation narrative, but today’s move reflects the market’s focus on the timeline for the next growth driver rather than the prior win. (investor.lantheus.com)

With LNTH-2501 now scheduled for an FDA decision on June 29, 2026, investors will likely track any additional regulatory communications, launch-prep commentary, and how management frames the cadence of 2026 milestones. Separately, the company has highlighted an August 13, 2026 PDUFA date for MK-6240, keeping another high-visibility catalyst on the calendar for the second half of the year. (lantheusholdings.gcs-web.com)